Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Tight Junction Targeting.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CLDN1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLDN1 Recombinant Proteins & Fragment Loops High purity (>95%), Endotoxin controlled (<1 EU/µg). Sequence Verified. HEK293 expressed options. |
View CLDN1 Products |
| Gene Delivery | CLDN1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Preserves native 4-transmembrane conformation for cell-based assays. |
View CLDN1 Products |
| Benchmark Ab | Anti-CLDN1 Recombinant Antibody Sequence-derived from clinical benchmark candidates. Recombinant positive control. |
View CLDN1 Products |
| Validator | CLDN1 siRNA Set For target knockdown validation and assay specificity controls. |
View CLDN1 Products |
| Related Target A | CLDN18.2 Crucial for selectivity counter-screening to prevent off-target toxicity in Claudin-targeted therapies. |
View CLDN18.2 Products |
| Related Target B | CLDN6 Key oncofetal tight junction protein used in specificity panels for multi-specific antibodies. |
View CLDN6 Products |
| Related Target C | CD3 Required for validating CLDN1 x CD3 bispecific T-cell engagers (BiTEs). |
View CD3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native 4-Transmembrane Conformation (Loss of epitopes in soluble formats) | Lentivirus Premade Particles for stable cell line generation, enabling flow cytometry and cell-based binding assays with intact structural folds. |
| Subfamily Cross-Reactivity (Distinguishing CLDN1 from CLDN18.2 or CLDN6) | High-purity homolog panel proteins (CLDN18.2, CLDN6) strictly verified by mass spectrometry for rigorous counter-screening. |
| Lack of Reliable Reference Controls | Sequence-verified clinical benchmark antibodies (biosimilars) expressed in mammalian hosts. |
| False Positive Signals in Binding Assays | Validated siRNA sets included for target knockdown verification in screening cells. |
Live CLDN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Claudin-targeted therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific T-cell engagers and antibody-drug conjugates (ADCs). While CLDN18.2 has paved the clinical path, CLDN1 is emerging as a critical target in solid tumors (such as colorectal, ovarian, and non-small cell lung cancers) and fibrotic diseases. As first-generation therapies reach clinical trials, the next wave of R&0 is targeting tumor-selective epitopes and pH-sensitive binding to avoid on-target, off-tumor toxicities in healthy epithelial tissues.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific Antibodies (T-Cell Engagers) | Boehringer Ingelheim, Amgen | Colorectal Cancer, Ovarian Cancer | Selectivity Assay (Need CLDN18.2 & CLDN6 counter-screens to verify no off-target T-cell activation) |
| Antibody-Drug Conjugates (ADCs) | Elucida Oncology, Astellas | Advanced Solid Tumors, Triple-Negative Breast Cancer | Internalization Assay (Need stable cell lines expressing native CLDN1 conformation) |
| Monoclonal Antibodies & Inhibitors | Academic Institutions, Biotech Startups | HCV Infection, Liver Fibrosis, Solid Tumors | Epitope Mapping & Affinity Verification (Need sequence-verified benchmark controls) |